<DOC>
	<DOCNO>NCT02198651</DOCNO>
	<brief_summary>A Phase 4 Trial Assessing ImPact Residual Inflammation Detected via Imaging TEchniques , Drug Levels Patient Characteristics Outcome Dose TaperIng Adalimumab Clinical Remission Rheumatoid ArThritis ( RA ) Subjects ( PREDICTRA ) .</brief_summary>
	<brief_title>A Phase 4 Trial Assessing ImPact Residual Inflammation Detected Via Imaging TEchniques , Drug Levels Patient Characteristics Outcome Dose TaperIng Adalimumab Clinical Remission Rheumatoid ArThritis ( RA ) Subjects ( PREDICTRA )</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Connective Tissue Diseases</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>1 . Subject diagnosis rheumatoid arthritis ( RA ) define 1987 revised American College Rheumatology ( ACR ) classification criterion and/or ACR /European League Against Rheumatism ( EULAR ) 2010 classification criterion ( duration since diagnosis ) . 2 . Subject must meet following criterion : Must treat adalimumab 40 mg sc eow least 12 month prior Week 0 Visit Must treat concomitant MTX stable dose ( oral , sc im dose ) least 12 week prior Week 0 Visit MTX , must treat allow csDMARDs stable dose least 12 week prior Week 0 Visit treat csDMARDs must maintain regimen least 12 week prior Week 0 Visit . 3 . Subject must sustain clinical remission base following : At least one document 4 3 ( PGA available ) variable DAS28 ( ESR ) DAS28 ( CRP ) &lt; 2.6 ( calculate base documented component DAS28 ) patient chart 6 month longer prior Screening Visit ; 4 variable DAS28 ( ESR ) assess Screening &lt; 2.6 , component include ESR assess Screening . 4 . If subject receive concomitant allow csDMARDs ( addition MTX ) dose must stable least 12 week prior Week 0 Visit ( e.g. , chloroquine , hydroxychloroquine , sulfasalazine , gold formulation [ include auranofin , gold sodium thiomalate , aurothioglucose ] and/or leflunomide ) . 5 . If subject receive concomitant oral corticosteroid , prednisone equivalent must &lt; 10 mg/day dose must stable least 4 week prior Screening Visit . 6 . If subject receive concomitant nonsteroidal antiinflammatory drug ( NSAIDs ) , tramadol equivalent opioids and/or nonopioid analgesic , dose and/or therapeutic scheme must stable least 4 week prior Week 0 Visit . 7 . Subject must able willing provide write informed consent comply requirement study protocol . 1 . Any 4 3 ( PGA available ) variable DAS28 ( ESR ) DAS28 ( CRP ) ( calculate base documented component DAS28 ) assess within 6 month prior Screening Visit â‰¥ 2.6 . 2 . Subject additional concomitant biological diseasemodifying antirheumatic drug ( bDMARD ) ( include limit abatacept , anakinra , certolizumab , etanercept , golimumab , infliximab , rituximab tocilizumab ) . 3 . Subject treat intraarticular parenteral corticosteroid within last four week Screening . 4 . Subject undergone joint surgery within 12 week Screening ( joint assess magnetic resonance imaging ( MRI ) and/or ultrasound ) . 5 . Subject medical condition preclude MRI ( e.g . magnetic activate implanted device cardiac pacemaker , insulin pump , neuro stimulators , etc . metallic device fragment clip eye , brain spinal canal hand/wrist undergo MRI ) 6 . Subject medical condition preclude contrast MRI gadolinium [ e.g . nephrogenic systemic fibrosis , previous anaphylactic/anaphylactoid reaction gadolinium contain contrast agent , pregnancy breast feeding , severe renal insufficiency estimate Glomerular Filtration Rate ( eGFR ) 0 mL/min/1.73m2 Screening , hepatorenal syndrome , severe chronic liver function impairment ] 7 . Subject treated investigational drug chemical biologic nature within minimum 30 day five halflives ( whichever longer ) drug prior Screening Visit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Magnetic Resonance Imaging</keyword>
	<keyword>Taper</keyword>
	<keyword>Anti-rheumatic drug</keyword>
	<keyword>Arthritis</keyword>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>Drug Level</keyword>
	<keyword>Flare</keyword>
	<keyword>Ultrasound</keyword>
	<keyword>Reduced dose</keyword>
	<keyword>Remission</keyword>
	<keyword>Adalimumab</keyword>
	<keyword>Biomarker</keyword>
</DOC>